Drug intelligence / Profile preview

WJB001

Development stage: Phase 2
Lead developer: Wigen Biomedicine Technology
Modality: Small Molecules
Administration: Oral

Overview

WJB001 is an oral, broad-spectrum small molecule drug under development by Wigen Biomedicine in cooperation with Junshi Biosciences for the treatment of advanced solid tumors. It is being evaluated in a phase I/II clinical trial for its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced tumors, including those with CCNE1 overexpression or amplification such as uterine serous carcinoma, high-grade serous ovarian cancer, fallopian tube cancer, and peritoneal cancer[1][2][3]. The precise mechanism of action has not been publicly disclosed.

Other names: WJB001WJB-001WJB 001

Targets

XPO1 (Exportin-1)

Beyond the preview

Go deeper on WJB001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WJB001.

Explore the full profile